Literature DB >> 24761987

Epidemiology of systemic mastocytosis in Denmark.

Sarah S Cohen1, Stine Skovbo, Hanne Vestergaard, Thomas Kristensen, Michael Møller, Carsten Bindslev-Jensen, Jon P Fryzek, Sigurd Broesby-Olsen.   

Abstract

Mastocytosis is a heterogeneous group of diseases characterized by abnormal proliferation of mast cells. Systemic mastocytosis (SM), in which abnormal mast cells are present in tissues beyond the skin, is divided into seven subcategories with varying degrees of severity and prognosis. Very little is known about the epidemiology of SM and its subcategories. This retrospective cohort study of 548 adults with SM diagnosed 1997-2010 was constructed using linked Danish national health registries. The most common subtype of mastocytosis was indolent SM (including urticaria pigmentosa) (n = 450; 82%), followed by SM with subtype unknown (n = 61; 11%), SM with associated clonal haematological non-mast cell lineage disease (n = 24; 4%), aggressive SM (n = 8; 2%), and mast cell leukaemia (n = 5; 1%). The incidence rate for SM (all subtypes including urticaria pigmentosa) was 0·89 per 100 000 per year. Cumulative incidence was 12·46 per 100 000, and the 14-year limited-duration prevalence as of 1 January, 2011 was 9·59 per 100 000. This nationwide cohort from Denmark is the first population-based epidemiological study of mastocytosis. In this cohort of patients aged 15 years and older, SM was found to be overall relatively rare with notable variation by subtype for patient characteristics, survival and epidemiological measures.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Denmark; aggressive systemic mastocytosis; epidemiology; indolent systemic mastocytosis; urticaria pigmentosa

Mesh:

Year:  2014        PMID: 24761987     DOI: 10.1111/bjh.12916

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  36 in total

Review 1.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

2.  First Identification of an Inherited TPSAB1 Quintuplication in a Patient with Clonal Mast Cell Disease.

Authors:  Vito Sabato; Jack Chovanec; Margaretha Faber; Joshua D Milner; Didier Ebo; Jonathan J Lyons
Journal:  J Clin Immunol       Date:  2018-05-11       Impact factor: 8.317

Review 3.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

4.  Genome-wide association study identifies novel susceptibility loci for KIT D816V positive mastocytosis.

Authors:  Gabriella Galatà; Andrés C García-Montero; Thomas Kristensen; Ahmed A Z Dawoud; Javier I Muñoz-González; Manja Meggendorfer; Paola Guglielmelli; Yvette Hoade; Ivan Alvarez-Twose; Christian Gieger; Konstantin Strauch; Luigi Ferrucci; Toshiko Tanaka; Stefania Bandinelli; Theresia M Schnurr; Torsten Haferlach; Sigurd Broesby-Olsen; Hanne Vestergaard; Michael Boe Møller; Carsten Bindslev-Jensen; Alessandro M Vannucchi; Alberto Orfao; Deepti Radia; Andreas Reiter; Andrew J Chase; Nicholas C P Cross; William J Tapper
Journal:  Am J Hum Genet       Date:  2021-01-08       Impact factor: 11.025

Review 5.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

Review 6.  The international consensus classification of mastocytosis and related entities.

Authors:  Roos J Leguit; Sa A Wang; Tracy I George; Alexandar Tzankov; Attilio Orazi
Journal:  Virchows Arch       Date:  2022-10-10       Impact factor: 4.535

7.  Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.

Authors:  Martin Gehlen; Niels Schmidt; Michael Pfeifer; Subathira Balasingam; Michael Schwarz-Eywill; Anna Maier; Mathias Werner; Heide Siggelkow
Journal:  Calcif Tissue Int       Date:  2021-07-05       Impact factor: 4.333

8.  Clinical and Molecular Diagnostic Evaluation of Systemic Mastocytosis in the South-Eastern Hungarian Population Between 2001-2013--A Single Centre Experience.

Authors:  Imelda Marton; László Krenács; Enikő Bagdi; Annamária Bakos; Judit Demeter; Zita Borbényi
Journal:  Pathol Oncol Res       Date:  2015-11-06       Impact factor: 3.201

9.  International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.

Authors:  Wolfgang R Sperr; Michael Kundi; Ivan Alvarez-Twose; Bjorn van Anrooij; Joanna N G Oude Elberink; Aleksandra Gorska; Marek Niedoszytko; Karoline V Gleixner; Emir Hadzijusufovic; Roberta Zanotti; Patrizia Bonadonna; Massimiliano Bonifacio; Cecelia Perkins; Anja Illerhaus; Chiara Elena; Serena Merante; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Mohamad Jawhar; Anna Belloni Fortina; Francesca Caroppo; Knut Brockow; Alexander Zink; David Fuchs; Alex J Kilbertus; Akif Selim Yavuz; Michael Doubek; Hans Hägglund; Jens Panse; Vito Sabato; Agnes Bretterklieber; Dietger Niederwieser; Christine Breynaert; Karin Hartmann; Massimo Triggiani; Boguslaw Nedoszytko; Andreas Reiter; Alberto Orfao; Olivier Hermine; Jason Gotlib; Michel Arock; Hanneke C Kluin-Nelemans; Peter Valent
Journal:  Lancet Haematol       Date:  2019-10-31       Impact factor: 18.959

10.  The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.

Authors:  Judith Leyens; Tim Th A Bender; Martin Mücke; Christiane Stieber; Dmitrij Kravchenko; Christian Dernbach; Matthias F Seidel
Journal:  Orphanet J Rare Dis       Date:  2021-07-22       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.